Literature DB >> 19558791

Beta-catenin protein utilized by Tumour necrosis factor-alpha in porcine preadipocytes to suppress differentiation.

Xiao Luo1, Hui-Xia Li, Rong-Xin Liu, Zong-Song Wu, Ying-Juan Yang, Gong-She Yang.   

Abstract

The Wnt/beta-catenin signaling pathway alters adipocyte differentiation by inhibiting adipogenic gene expression. beta-catenin plays a central role in the Wnt/beta-catenin signaling pathway. In this study, we revealed that tumour necrosis factor-alpha (TNF-alpha), a potential negative regulator of adipocyte differentiation, inhibits porcine adipogenesis through activation of the Wnt/beta-catenin signaling pathway. Under the optimal concentration of TNF-alpha, the intracellular beta-catenin protein was stabilized. Thus, the intracellular lipid accumulation of porcine preadipocyte was suppressed and the expression of important adipocyte marker genes, including peroxisome proliferator-activated receptor-gamma (PPARgamma) and CCAAT/enhancer binding protein-alpha (C/EBPalpha), were inhibited. However, a loss of beta-catenin in porcine preadipocytes enhanced the adipogenic differentiation and attenuated TNF-alpha induced anti-adipogenesis. Taken together, this study indicated that TNF-alpha inhibits adipogenesis through stabilization of beta-catenin protein in porcine preadipocytes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19558791     DOI: 10.5483/bmbrep.2009.42.6.338

Source DB:  PubMed          Journal:  BMB Rep        ISSN: 1976-6696            Impact factor:   4.778


  2 in total

1.  [Tumor necrosis factor-α and transforming growth factor-β1 balance liver stem cell differentiation in cholestatic cirrhosis].

Authors:  Bo Yang; Qing Luo; Quan Kang; Jian Wang; Cheng Xiao; Zhi-Peng Li; Meng-Jia Gong; Yang Bi
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-04-20

2.  1,25(OH)2D3 inhibits osteogenic differentiation through activating β‑catenin signaling via downregulating bone morphogenetic protein 2.

Authors:  Xiaofeng Han; Naifeng Zhu; Yihan Wang; Guangqi Cheng
Journal:  Mol Med Rep       Date:  2020-10-20       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.